Abstract
Introduction
establishment of measurements quantifying iAGT, oxi-AGT, and red-AGT levels is 73 important for accurate assessments of intact renin substrate in both its forms.
74
Rahgozar and colleagues established an ELISA system to determine oxi-AGT and red-
75
AGT levels (14) . In the ELISA, biotins bind to free-thiol groups in AGT by disulfide 76 bonds, which enables detection of only red-AGT via formation of avidin-biotin complex 77 (14) . While this assay system can be a useful tool, this method detects red-AGT in both 78 intact AGT and des-Ang I AGT. It is important to determine oxi-AGT and red-AGT levels 79 of iAGT to evaluate levels of renin substrate and its affinity to renin. We recently 80 developed direct quantitative methods to measure total AGT in plasma of humans (18) as 81 well as of rodents (24). In addition, there are commercial intact AGT ELISAs (IBL) in 82 which a sandwich ELISA technique using both anti-Ang I and anti-AGT antibodies is 83 employed. However, in the course of our studies, we discovered that the iAGT ELISA only 84 measured the reduced form of AGT. Thus, we developed a procedure that involves treating 85 samples with a reducing agent in order to obtain an accurate measurement for total iAGT.
86
In the current study, we report the iAGT, oxi-AGT, and red-AGT levels in rat and mouse 87 plasma utilizing this modification of the commercially available ELISA kits.
89

Methods
90
Animals and sample collection 91 Male C57BL/6J mice (18 week-old) and Sprague-Dawley rats (8 week-old) were used.
92
The animal experimental protocol was approved by the Animal Care and Use Committee of
93
Tulane University. The rats were housed in a constant temperature room with 12 hours 94 conducted.
96
Blood samples were collected from conscious animals by cardiac puncture using 1 ml each plasma sample by mixing with the inhibitor cocktail was calculated based on the 106 plasma volume and hematocrit ratio which was determined separately. The dilution factor 107 in each sample was used to calculate tAGT, iAGT, oxi-AGT, and red-AGT levels after 108 ELISA measurements. 
173
In the western blot analysis, mouse plasma AGT linearized by LDS and reduced by DTT 174 treatments was detected by an anti-AGT antibody ( Fig. 2A) . In the same volume of mouse 175 plasma (1 μL), AGT linearized by LDS but not reduced was also detected on the membrane 176 ( Fig. 2A) . Intensities of the detected bands in Fig. 2A were identical, suggesting equal 177 loading. These bands exhibited slightly different migrations in the gel ( Fig. 2A,   178 approximately 48 and 50 kDa, respectively) because of conformational alterations due to 179 dissociation of disulfide bonds. These plasma samples were used to test immunoreactivity 180 to an anti-Ang I antibody (Fig. 2B) . The reducing treatment of the plasma sample with
181
DTT markedly increased immunoreactivity of AGT to the anti-Ang I antibody (Fig. 1B) , (Fig. 2C) . However, the immunoreactive spot was not detected by the anti-Ang I
191
antibody when the plasma did not receive the reducing treatment (Fig. 2D) . On the other 192 hand, the immunoreactivity to the anti-Ang I antibody was clearly observed in plasma samples (Fig. 2D) . (Fig. 2) , plasma samples were pre-treated with DTT in the iAGT assay to obtain the 199 maximum immunoreactivity to anti-Ang I antibody used in the ELISA. Total AGT levels 200 in rat plasma were 1839.2±138.8 ng/mL (N=12, Fig. 3A ). iAGT levels in rat plasma were 201 983.3±56.3 ng/mL (N=12, Fig. 3A) , which is 53.5% of the total AGT levels. In mouse 202 plasma (N=12), total AGT and iAGT levels were 1081.9±76.8 ng/mL and 243.2±16.6 203 ng/mL, respectively (Fig. 3B) . Thus, 22.5% of the total AGT was intact AGT in mouse plasma. The DTT treatment maintained the linearity of standard curve in the iAGT ELISA 205 (Fig. 3C) . 
235
Since the results of western blot analyses demonstrated that the anti-Ang I antibody 236 exhibits the immunoreactivity only to red-AGT, plasma oxi-AGT and red-AGT levels were 237 quantified using reduced-and non-reduced plasma samples and intact AGT ELISA. In rat 238 and mouse plasma, the amount of iAGT detected by the ELISA without the reducing 239 treatment using DTT was very low (204.8 ng/mL in rat and 15.5 ng/mL in mouse). These 240 numbers suggested very low levels of endogenous red-AGT in the plasma. In particular, 241 the ratio of oxi-AGT and red-AGT in mouse plasma iAGT was 16:1, suggesting that much 242 of iAGT is oxidized in mouse plasma under normal conditions. The results of western blot 243 and dot blot analyses also showed very low levels of AGT band (Fig. 2B ) and no AGT spot 244 (Fig. 2D) detected by an anti-Ang I antibody when plasma did not receive the reducing 245 treatment using DTT, supporting the low levels of naturally occurring red-AGT in rodent 246 plasma observed in ELISAs. Since oxi-AGT exhibits higher affinity to renin than red-AGT 247 (22), the high ratio of oxi-AGT in mouse plasma may lead to greater levels of AGT cleavage by renin, explaining the lower levels of iAGT in mouse than rat. In contrast to the 249 results in this study, previous studies have reported high ratio of red-AGT in human blood; 250 about 40% (22) and >90% (14) of red-AGT in total AGT. The inconsistency of the findings 251 may be because in the previous study measured red-AGT and oxi-AGT were factored by 252 total AGT, which included cleaved des-Ang I-AGT, and the possible differences between 253 human and rodent circulating AGT.
254
In conclusion, this study describes a specific method to quantify total iAGT and to 255 estimate the ratio of oxi-AGT and red-AGT in rodent plasma by modifying the 256 commercially available ELISAs. We document that total circulating AGT concentrations 257 in mice are lower than in rats and that the fraction of iAGT is greater in rat plasma than 258 mouse plasma. The lower availability of plasma iAGT in mice than rats suggests that it 259 may be a limiting factor in Ang I formation in this species. Accumulation of experimental 260 evidence will be required to precisely evaluate oxi-AGT and red-AGT levels under 261 different physiological and disease conditions. 
